Cargando…

Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective

Targeted cancer therapies using immunotoxins have achieved remarkable efficacy in hematological malignancies. However, the clinical development of immunotoxins is also faced with many challenges like anti-drug antibodies and dose-limiting toxicity issues. Such a poor efficacy or safety ratio is also...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengyu, Mei, Sen, Yang, Yi, Shen, Yuelei, Chen, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344849/
https://www.ncbi.nlm.nih.gov/pubmed/35928456
http://dx.doi.org/10.1093/abt/tbac014